Introduction {#s1}
============

Metformin is one of the most commonly used diabetes treating agents \[[@R01]\]. It has proved to be very effective, with a wide spectrum of efficacy, safety, as well as being an agent that works at different spots in diabetes pathogenesis paradigm \[[@R01]\]. Metformin is now being used for over 60 years in many parts of the world. During these six decades, plenty of data showed beneficial effects of metformin apart from diabetes. Many diabetes associated conditions, like polycystic ovary disease and fatty liver disease, showed remarkable improvement upon using metformin \[[@R02], [@R03]\]. Data showed a protective effect of metformin in reducing cardiovascular complications, not only in diabetes patients but even those with a prediabetes state on the long term \[[@R04]\]. Moreover, metformin showed a beneficial effect in some studies in reducing the prevalence of different malignant conditions, and it helped in treating some of them when concomitantly used with other agents. From an endocrine perspective, some studies pointed towards the effect of the metformin on the thyroid function test, even in euthyroid patients. Nonetheless, metformin reduced the size of the thyroid nodule in some small papers in the literature.

In this review, we shall highlight the systemic effects of metformin. We will focus mainly on the non-diabetes-related effects. Reviewed literature included randomized controlled trials, observational trials, and review articles. We have reviewed papers with the primary objective of assessing the non-diabetes related health issues.

We have classified the results according to the area of metformin effect. These areas included the effect on inflammation modulation, weight reduction, and thyroid diseases and so on. In the cancer section, since it is the most studied area with metformin after diabetes, we have subdivided it according to the type of cancer that has been studied to make it easier to assess. Short elaboration will precede all this on the proposed mechanisms of action of metformin molecule.

Mechanism of Action of Metformin {#s2}
================================

The metformin molecule works in the humans' bodies at the level of the liver and peripheral tissues, basically, by downsizing the glucose output from the liver, as well as by enhancing the utilization at the peripheral tissues (muscles). This process takes place through the activation of adenosine monophosphate-activated protein kinase (AMPK). The AMPK is the cell regulatory pathway that reduces the energy expenditure at the cellular level. In humans, AMPK is essential for the metabolism of glucose and fatty acids, through reduction of the gluconeogenesis and fatty acids synthesis in the liver, and enhancing glucose uptake, and the fatty acids oxidation by peripheral tissues \[[@R01]\]. Moreover, mitochondrial metabolism has also been found to be down-regulated by the metformin, which helps in the less gluconeogenesis, and perhaps in, the unexpectedly discovered, tumor modulation privilege of metformin \[[@R07], [@R08]\]. Recently, a new pathway has been described to play a role in the anti-neoplastic effect of metformin; metformin was found to modulate adenosine A1 receptor (ADORA1) expression in human colorectal cancer cells \[[@R09]\]. ADORA1 receptors are essential in the cellular energy supply. Thus cancer cells will be energy deprived in case of down-regulation of those receptors. Though the AMPK primarily activates ADORA1, it is considered an entirely different pathway that reduces the number of the colorectal neoplastic cells and induces the apoptosis \[[@R09]\]. Further organ-specific pathways will be discussed in the article below.

Metformin as an anti-inflammatory agent {#s2a}
---------------------------------------

It has been hypothesized that inhibition of the NF-kB by metformin down-regulates the inflammatory response; this might be the key answer to the reduction in the cardiovascular events \[[@R10]\]. However, other studies have challenged this hypothesis by demonstrating minimal \[[@R11]\], or no influence on the inflammatory response \[[@R12]\].

Metformin as an anti-oxidant {#s2b}
----------------------------

This privilege is still to be explained by scientists. The hypotheses include lowering the reactive oxygen species, up-regulation of uncoupled protein 2 in the fat cells, as well as the AMPK system activation \[[@R01], [@R08], [@R13]\]. This as mentioned above reduces gluconeogenesis, and increase fatty acids metabolism, as well as B-oxidation in the fat tissues.

Metformin improves endothelial function {#s2c}
---------------------------------------

There is substantial evidence that links dysglycemia with an unfavorable endothelial health, increasing the risk of thrombus formation \[[@R12]\]. The mechanism of this is still controversial; endothelial function modulation was suggested to be directly from the metformin molecule \[[@R14], [@R15]\] or via insulin resistance improvement, or at most extreme, no endothelial benefits at all \[[@R15]\].

Metformin as a weight reducing agent {#s2d}
------------------------------------

Metformin is not a weight reducing agent on its own; many researchers have concluded that metformin might halt the weight gain caused by other diabetes or diabetes-related medications like insulin, thiazolidinedione, sulfonylureas, antipsychotics, etc. \[[@R16]\].

The mechanism behind weight reduction is well established. The weight changes are more prominent in patients with impaired glucose tolerance \[[@R20]\], unlike, obese people who do not have diabetes in whom metformin failed to reduce weight \[[@R21]\].

Many reports have elaborated on the mechanistic explanation of metformin and weight loss, which has been attributed to modest reduction in the carbohydrates uptake in the gut as well as the modulation of the vicious cycle of the insulin resistance, and reduction in leptin levels, in addition to the augmentation of the glucagon-like peptide-1 effects on fat cells \[[@R22]\].

Metformin and the thyroid gland {#s2e}
-------------------------------

Unlike type 1 diabetes, there is no clear association between T2DM and the thyroid illnesses. But the treatment (specifically metformin) might have some implications on the status of the thyroid function parameters. In the last decade, many reports have highlighted the possibility of metformin affecting the thyroid-stimulating hormone (TSH) and concluded that it has no effect on thyroid hormone (T3 and T4) \[[@R25], [@R26]\].

In a recent study, Cappelli et al have demonstrated a statistically significant difference in the level of the TSH (P \< 0.05), in diabetic patients who were started on metformin, while the level of T4 and T3 remained unchanged over 1 year. The change took place in the group with an already existing hypothyroidism whether they are on treatment or not, while the euthyroid group had their TSH unchanged. Therefore, the authors recommended that TSH needs to be checked in patients with T2DM even without a concomitant hypothyroidism \[[@R27]\]. An interesting study from Malta evaluated the effect of the metformin on the TSH and T4. The study included 238 individual with type 2 diabetes (121 males and 117 females); nearly half of them were on metformin. They have excluded those with history of thyroid illness, recent major illness, and those who are receiving active thyroid treatment. TSH was numerically lower in metformin-treated patients, without reflecting statistical significance. The T4 was higher in the females who were on metformin compared to the control group (18.4 vs. 16.5 pmol/L) (P \< 0.01). They concluded that the metformin is likely affecting the thyroid function through inhibition of the peripheral conversion of thyroxine to triiodothyronine \[[@R28]\].

Metformin and the nervous system {#s2f}
--------------------------------

The role of metformin in the nervous system is uniquely interesting. We know now that modulation of diabetes reduces all cardiovascular mortalities \[[@R05]\]. Out of the context of diabetes mellitus and the related vascular insults, metformin was thought to play a minor role in Alzheimer's disease, the disease that used to be unofficially labeled as type 3 diabetes. In Alzheimer's disease, there is remarkable progressive insulin resistance of the brain cells, leading to formation and accumulation of the amyloid cells (due to lack of insulin effect on the cells) after a sequence of chemical transformations \[[@R29], [@R30]\].

The role of metformin in those cascades is not clear. But it is quite known that brain cells are dependent on the glucose for survival, as well as the high probability of oxidative injuries since they have low antioxidant enzymes content and frequent exposure to oxidative stresses \[[@R31], [@R32]\]. Moreover, activation of the AMPK pathway is thought to play a role in reducing the insulin resistance and the oxidative stress. And, as mentioned earlier, metformin was found to accelerate the activation of the AMPK \[[@R01], [@R31]\]. Activation of AMPK by metformin could partly help in understanding the minor protective role of metformin in Alzheimer's disease. Moreover, AMPK is also expected to play a cardinal role in the pathophysiology of other various neurological diseases like Parkinson's disease, and amyotrophic lateral sclerosis.

Another way of oxidative stress augmentation is the mitochondrial metabolism dysfunction. There is a protein called permeability transition protein; this protein is responsible for the programmed cell death (apoptosis). When the permeability transition protein is released, it stimulates the production of the cellular apoptotic proteins, which result later in the cell death. Metformin was found to play a pivotal role in this cascade. Metformin breaks the cycle of the permeability transition pore in the mitochondria, as well as induces the production of the cytochrome-c. Both effects of metformin in the mitochondria delay the programmed cell death \[[@R32], [@R33]\].

Metformin and the blood homeostasis {#s2g}
-----------------------------------

It was mentioned earlier that metformin reduces the incidence of cardiovascular events in diabetes patients. This takes place through various cascades (glycemia and non-glycemia related cascades). Metformin, in high doses, was shown to various coagulation factors in humans. Metformin reduces the systemic production of the tissue type plasminogen activator, Von Willibrand factor, and plasminogen activator inhibitor \[[@R34]\]. In addition to that, metformin was found to modulate the fibrin threads formation; this takes place by reducing the factor XIII functions and structural modeling of the fibrin threads \[[@R12]\]. Nonetheless, metformin was found to reduce the levels of plasminogen activator inhibitor-1, and Von Willibrand factor from the unhealthy endothelium in patients with no underlying diabetes mellitus \[[@R35]\].

Metformin and HIV treatment-related side effects {#s2h}
------------------------------------------------

It is known that antiretroviral agents (HIV treatment) lead to devastating fats and other metabolic consequences such as insulin resistance, dyslipidemia, worsening of the blood glucose levels, and lipodystrophy \[[@R36]\]. Those side effects might take place in as high as 80% of the anti-retroviral therapy treated patients \[[@R36]\]. Strenuous exercise and dietary modification reduce the morphological as well as the chemical consequences of the antiretroviral agents. Moreover, metformin, when added to the lifestyle modification tools, can effectively prevent those consequences, but the effect was confined basically to an improvement of visceral fat distribution \[[@R37], [@R38]\]. Nonetheless, metformin with antiretroviral agents was found to be efficiently reducing the risk of insulin insensitivity, hyperglycemia, weight gain, dyslipidemia, as well as improvement in the flow-mediated vascular dilatation \[[@R37]\].

Metformin and Cancers {#s3}
=====================

Metformin and liver cancer {#s3a}
--------------------------

An interesting meta-analysis from China, which looked at all the trials that assessed liver cancer risk modulation with metformin, the authors have looked into five trials out of the PubMed and SciVerse Scopus databases. The total number of patients studied was approximately 105,495. In this meta-analysis, they concluded that metformin appears to play a role in the reduction of liver cancer risk in type 2 diabetes patients. The authors have called for further mechanistic, well-designed trials to consolidate this conclusion \[[@R40]\].

Metformin and pancreatic cancer {#s3b}
-------------------------------

Many studies have evaluated this point, having the possible link between diabetes and pancreatic cancer. For instance, in a meta-analysis from Australia, Huxley, and his colleagues assessed the computer-based literature from 1966 to 2005. The researchers have found a hint to a causal relationship between type 2 diabetes and pancreatic cancer. An interesting finding in this study is that those who had a shorter duration of diabetes had a higher risk of pancreatic cancer development \[[@R41]\].

Another study has looked into the patients who were going for surgery for pancreatic cancer. They have found a statistically significant lower risk of mortality in patients with pancreatic cancer if they were on metformin. The authors called for further studies to know more about the anti-tumorigenic privilege of metformin in this context \[[@R42]\].

Metformin and breast cancer {#s3c}
---------------------------

As already mentioned in this article, the principal mechanism of action of metformin is by exerting a direct effect on AMPK; this occurs when metformin lowers the ATP ratio in cells causing energetic stress and thus stimulating the AMPK pathway responsible for energy homeostasis. Excess energy, in turn, will signal the need to decrease the energy consumption and thus switch off cell growth and proliferation causing the desired cytotoxic effect on breast cells. Besides, metformin exerts an indirect effect on cells by lowering the insulin levels, which decreases the levels of P13k pathway and thus inhibit cell growth and proliferation \[[@R43]\]. Metformin reported a better pathologic complete response rate when taken regardless if the patient had diabetes or not \[[@R44]\]. In another laboratory study, metformin was tested at different breast cancer differentiation phases; it showed inhibitory signals at early stages of cell differentiation of breast cancer \[[@R45]\]. It is worth mentioning that higher doses of metformin are needed to attain the antineoplastic effect (1.5 - 2.25 g), though this point needs further long-term data to support it \[[@R46]\].

Metformin and colorectal cancer {#s3d}
-------------------------------

A meta-analysis of five studies including 108,161 diabetic patients indicated a notable lower risk of colorectal carcinoma in those treated with metformin \[[@R47]\]. Also, an updated meta-analysis of studies reviewed up until 2015 augmented metformin's ability in lowering the risk of colorectal cancer and in improving the survival outcome in such patients \[[@R48]\]. Another recent systemic review and meta-analysis reported metformin superiority in lowering the risk of colorectal cancer as compared to other anti-diabetic modalities \[[@R49], [@R50]\]. Lee et al (2012) looked into 595 patients with colorectal cancer, and those on metformin had a lower risk of overall and cancer-related mortality (P = 0.15 and 0.37, respectively) \[[@R51]\].

Metformin and prostate cancer {#s3e}
-----------------------------

There is an ongoing debate between the use of metformin and the risk of prostate carcinoma. Many meta-analyses and studies are done. However, only a few showed the positive association of prostate cancer with metformin, while others appreciated metformin's effect in reducing the risk of developing prostate cancer \[[@R52]\]. Another debate is about the use of metformin and the outcome in patients with prostate cancer. Metformin improved the outcome of prostate cancer and overall mortality, as supported by many studies for the benefits of metformin as an adjuvant therapy for prostate cancer \[[@R53]\], like it did in many other earlier mentioned malignancies. However, two meta-analysis and studies are suggesting no proven benefits of what is expected by metformin on cancer cells \[[@R54]\].

Metformin and lung cancer {#s3f}
-------------------------

Sakoda et al in a cohort study showed no association between metformin use and risk of lung cancer regardless how long patients were on metformin or the maximum dose used. However, this finding applied to diabetic patients who were 40 years and older and did not include other factors like smoking for example \[[@R58]\]. Furthermore, similar evidence is found in literature such as the case-control analysis by Bodmer et al where they showed a neutral effect of metformin, favorable effect of sulphonylureas and higher incidences with insulin use \[[@R59]\]. Smiechowski et al included 115,293 oral hypoglycemics agent (OHA) users from the United Kingdom General Practice Research Database between 1988 and 2009, with 1,061 patients diagnosed with lung cancer during follow-up (rate 2.0/1,000 person-years). Metformin was not absolutely neutral in the cancer outcome, and they concluded that the results in other observational trials were biased in methodology and selection \[[@R60]\].

Looking from a different view, a retrospective cohort study by Wink et al concluded that diabetic patients on metformin diagnosed with locally advanced non-small cell lung cancer had a less chance of disease progression and metastasis when received concurrent chemo-radiotherapy and metformin than those who were not on metformin \[[@R61]\]. However, another meta-analysis including 17 studies showed metformin had no survival benefit when used as an adjuvant with chemo-radiotherapy while it conferred a better survival outcome to lung cancer patients including those on chemotherapy only \[[@R62]\]. These results were replicated in Menamin et al's study, which assessed lung cancer patient registry between 1998 and 2009, and they found a weak favorable outcome when metformin was on board before or after diagnosis \[[@R63]\]. Interestingly, in the same study, there was a weak negative impact on other hypoglycemic agents like sulphonylureas and thiazolidinedione \[[@R63]\]. Further prospective studies are needed since the data in this perspective are contradicting.

Metformin and thyroid cancer {#s3g}
----------------------------

Klubo-Gwiezdzinska et al published findings of metformin's anti-proliferative effects on differentiated thyroid cancers when they examined 34 patients with differentiated thyroid cancer (DTC) taking metformin versus 21 non-metformin using patients, tumor size was smaller, and progression was slower in the metformin group \[[@R64]\]. One of the theories in DTC response to metformin is the p70S6K/pS6 pathway that induces the cancer cell metabolic stress and the autophagy later \[[@R64]\]. Similar experimental findings by Klubo-Gwiezdzinska et al on medullary thyroid cancer (MTC) cells found slowness of cellular progression in metformin-treated patients. They stated that cyclin D1 (usually overexpressed in cancer cells) was remarkably inhibited, through inhibition of mTOR/p70S6K/pS6 signaling and down-regulation of pERK. Out of this sophisticated process, they concluded metformin could have a potential additional role in treating MTC \[[@R65]\], therefore, adding thyroid cancer to the list of cancers showing a decreased cancer-specific mortality with the use of metformin.

Metformin and endometrial cancer {#s3h}
--------------------------------

A 5-year retrospective analysis of metformin use with endometrial cancer showed a good outcome on the overall survival. However, data were not confined to non-diabetics only but included those diabetic patients who were kept on metformin, thus the results may be due to an improvement in all-cause mortality rather than being cancer-specific. Metformin's role in endometrial cancer recurrence remains unclear \[[@R66]\].

A recent study in 2016 explained the improvement of overall survival in patients with advanced endometrial cancer, undergoing chemotherapy while taking metformin. However, the drawback of the study was the end point as it was death due to any cause, not specifically due to the endometrium cancer \[[@R67]\]. Thus many studies have pointed towards the improvement in survival might be because of the patient's overall health improvement rather than the regression/resolution of endometrial cancer *per se* \[[@R68]\].

A prospective study on newly diagnosed endometrial cancer patients demonstrated the reduction in relevant serum and molecular markers by metformin in 7 or more days only. However, only 20 patients continued the trial, which calls for further elaboration on metformin's benefits by using a bigger sample size \[[@R68]\].

Another point that has not been described yet in the previously mentioned mechanisms of metformin on tumor cells is the FOXO1 pathway involvement. Zou et al found a new path that can be the start for further therapeutic agents in preventing endometrial cancer. It was depicted by the following: giving an AMPK inhibitor which in turn inhibited the FOXO1 pathway indicating the relationship between both the pathways and by injecting a silencing RNA for FOXO1 in endometrial cells which subsequently eradicated metformin's anti-proliferative effect.

In short, many studies promise the beneficial effect of metformin on endometrium cancer including progesterone-resistant cancer cells \[[@R71]\].

Metformin and cervical cancer {#s3i}
-----------------------------

Very limited data are available about metformin on cervical cancer suppression as most of the retrospective studies were confined to diabetics who were on metformin already.

However, one study by Xiao et al examined metformin's dynamics in cervical cancer cells and focused on the activity of LKB1 in these cells. The cell lines responsive to metformin were found to stimulate AMPK via LKB1 and prevent mTOR; in contrary, the non-responsive cells to metformin were those who were void of LKB1. Also, the writers detected that metformin was able to repress certain cervical cancer cell lines (such as those containing C33A, ME180 and CaSki) while being less effective against other cell lines (such as HeLa, HT-3 and MS751).

These outcomes indicated that metformin could have an adjuvant role in treating cervical cancer, especially in tumor cells containing LKB1 \[[@R72]\].

Metformin and renal cell cancer {#s3j}
-------------------------------

A published article in 2013 by Liu et al showed metformin requires a specific dose and times to be effective in preventing renal cell carcinoma (RCC). Another crucial step was its ability to activate the AMPK pathway that subsequently leads to inhibition of mTOR that is responsible for cell growth. Metformin also inhibited mTOR independently of AMPK, therefore making it more effective in wiping out the malignant cell growth. Finally, the article also discussed its additional anti-proliferative effect on RCCs by suppressing cyclin D gene which is responsible for cell growth \[[@R73]\].

In 2014, Yang et al revealed that metformin is also able to prevent RCC by regulation of the gene miR-26a, which will thereby inhibit cyclin D1 expression (responsible for cell growth) and up-regulate PTEN expression (a tumor suppressor gene) \[[@R75]\]. But on the clinical ground, metformin showed no association in preventing recurrence of RCC after its resection; however, future further studies are required \[[@R75]\].

Metformin and melanoma {#s3k}
----------------------

An article in 2011 by Tomic et al entertained an additional anti-proliferative effect of metformin in addition to AMPK activation. The activation of the AMPK ends cell proliferation, and subsequently, apoptosis develops within 96 h. Interestingly this article illustrated two findings: one is how metformin leads to phagocytosis of cells containing AMPK, which are malignantly mutated, whilst sparing the healthy cells containing AMPK. Secondly, metformin can reduce proliferation of tumor cells effectively in an AMPK-independent manner as well \[[@R76]\]. Further on in 2013, an update to this article showed metformin's anti-metastatic effects on aggressive malignancies like melanomas \[[@R77]\].

Conclusion {#s4}
==========

Metformin is one of the most widely prescribed antihyperglycemic agents. It is irreplaceable as first line hypoglycemic agent since decades, despite the development of numerous new hypoglycemic drugs due to its unique effect on glycemic control by addressing the insulin resistance. Being one of the older drugs in the field time has witnessed its good extra glycemic effects and it is worth doing some well-designed case-control studies and randomized controlled trials to confirm these benefits.
